Positive trials for FGFR2 inhibitors[73], [74], [75] and IDH1 inhibitors76 have led to FDA- and EMA-licensed treatments, and tumour agnostic therapies for BRAF V600E mutated,77 MSI-H,78NTRK-fused,79 and RET-fused80 tumours are also FDA-licensed. The gene discussed is IDH1; the disease is neoplasm.